Consensus review of the clinical utility of dna content cytometry in prostate cancer

Cytometry

Volumn 14, Issue 5, 1993, Pages 497-500

  Shankey, T Vincent ^a   Kallioniemi, Ollie‐Pekka ^c   Koslowski, James M ^b   Lieber, Michael L ^d   Mayall, Brian H ^c   Miller, Gary ^e   Smith, Gary J ^f  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CYTOMETRY; DNA CONTENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

DNA, NEOPLASM; FLOW CYTOMETRY; HUMAN; MALE; PLOIDIES; PROGNOSIS; PROSTATIC NEOPLASMS; S PHASE;

EID: 0027233583     PISSN: 01964763     EISSN: 10970320     Source Type: Journal    
DOI: 10.1002/cyto.990140508     Document Type: Article

References (38)

1. Early detection of prostate cancer
2. The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer
3. Evaluation of tumor progression by repeated fine needle biopsies in prostate adenocarcinoma: modal deoxyribonucleic acid value and cytological differentiation
4. Nuclear DNA analysis: The relevance of ploidy, DNA heterogeneity and phases of the cell cycle in 329 patients with prostatic carcinoma. A study on a follow‐up of eight years
5. DNA‐grading of prostatic carcinoma: prognostic validity and reproducibility
6. DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinoma
7. Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcome
8. Ploidy level determinations in high‐grade and low‐grade malignant variants of prostatic carcinoma
9. The prognostic significance of nuclear DNA content in prostatic carcinoma
10. DNA ploidy as a prognostic factor in prostatic carcinoma
11. Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison
12. Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence
13. DNA flow cytometry and histopathological grading of paraffin‐embedded prostate biopsy specimens in a survival study
14. The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma
15. Prediction of prognosis in untreated stage A2 prostatic carcinoma
16. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis
17. The prognostic significance of ploidy and DNA‐heterogeneity in the primary diagnosis and monitoring of patients with locally advanced prostatic carcinoma
18. Stage C prostatic adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis
19. Modal DNA values and estramustine‐binding protein (EMBP) as prognostic markers in prostatic cancer
20. Prognostic significance of the nuclear DNA content in localized prostatic adenocarcinoma
21. Radical prostatectomy after radiation therapy for cancer of the prostate: feasibility and prognosis
22. Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate
23. Long‐term follow‐up after radical prostatectomy: Identification of prognostic variables
24. Nuclear deoxyribonucleic acid content measured by static cytometry: Important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy
25. Flow cytometry of prostate cancer: relationship of DNA content to survival
26. Correlation between ploidy and prognosis in prostatic carcinoma
27. DNA flow cytometry in carcinoma of the prostate for diagnosis, prognosis and study of tumor biology
28. Flow cytometric analysis of DNA ploidy and S‐phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy
29. Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry
30. Flow cytometric DNA analysis of stage D2 prostatic carcinoma
31. Prognostic significance of nuclear DNA levels in prostatic carcinoma
32. Ploidy level and tumor progression in prostatic carcinoma
33. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors
34. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread
35. DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report
36. Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma
37. Guidelines for the implementation of clinical DNA cytometry